These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28683295)

  • 21. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
    Wick A; Newlin K
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 26. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
    Gribble FM
    Diabet Med; 2008 Aug; 25(8):889-94. PubMed ID: 18959599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D; López X
    Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut hormone polyagonists for the treatment of type 2 diabetes.
    Brandt SJ; Götz A; Tschöp MH; Müller TD
    Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 receptor agonists today.
    Marre M; Penfornis A
    Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
    Madsbad S
    Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incretins: what is known, new and controversial in 2013?
    Burcelin R; Thorens B;
    Diabetes Metab; 2013 Apr; 39(2):89-93. PubMed ID: 23523140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 39. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.